Bystronic passt Ausblick für das Geschäftsjahr 2026 an
» Report
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Archiv: Unternehmen
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
» Report
Partners Group statement regarding its evergreen vehicles
» Report
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
» Report
Interroll Annual General Meeting 2026: Shareholders approve all proposals
» Report
ECB PRESS RELEASE Monetary policy decisions
» Report
EZB PRESSEMITTEILUNG Geldpolitische Beschlüsse
» Report
Partners Group targets USD 1.5 billion for latest real estate secondaries program
» Report
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
» Report
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
» Report
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
» Report
Mikron hosts the H1 2026 results media and analysts webcast on July 17, 2026
» Report
DKSH Enters Strategic Distribution Partnership with BridgeBio to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for ATTR-CM in Selected Asia Pacific Markets
» Report
HBM Healthcare Investments profitiert vom erfolgreichen Börsengang von Parabilis Medicines
» Report
Implenia renforce ses compétences en ingénierie et en planification en reprenant Zigmo Engineering
» Report
Implenia stärkt Engineering- und Planungskompetenzen durch Übernahme von Zigmo Engineering
» Report
Curatis Increases Revenue Growth Guidance for 2026
» Report
Zurich Airport Key traffic figures May 2026
» Report
Flughafen Zürich Verkehrszahlen Mai 2026
» Report
FDA News Release: FDA Expands Sunscreen Options for the First Time in 20 Years
» Report
